Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Niranjan Sudhakar"'
Autor:
John M. Ketcham, Jacob Haling, Shilpi Khare, Vickie Bowcut, David M. Briere, Aaron C. Burns, Robin J. Gunn, Anthony Ivetac, Jon Kuehler, Svitlana Kulyk, Jade Laguer, J. David Lawson, Krystal Moya, Natalie Nguyen, Lisa Rahbaek, Barbara Saechao, Christopher R. Smith, Niranjan Sudhakar, Nicole C. Thomas, Laura Vegar, Darin Vanderpool, Xiaolun Wang, Larry Yan, Peter Olson, James G. Christensen, Matthew A. Marx
Publikováno v:
Journal of Medicinal Chemistry. 65:9678-9690
SOS1 is one of the major guanine nucleotide exchange factors that regulates the ability of KRAS to cycle through its "on" and "off" states. Disrupting the SOS1:KRAS
Autor:
James G. Christensen, Peter Olson, Pasi A. Jänne, Kyriakos P. Papadopoulos, Piro Lito, Sai-Hong Ignatius Ou, Melissa L. Johnson, Igor I. Rybkin, Matthew A. Marx, Douglas P. Cassidy, Emanuel F. Patricoin, Elisa Baldelli, Mariaelena Pierobon, Jeremy Barton, Richard C. Chao, Karen Velastagui, Adam Pavlicek, Julio Fernandez-Banet, Sole Gatto, Yaohua Xue, Guy P. Vigers, John P. Fischer, Jay B. Fell, Michael R. Burkard, Joshua A. Ballard, Brian R. Baer, Vickie Bowcut, Niranjan Sudhakar, David M. Briere, Ruth Aranda, Andrew Calinisan, Lauren Hargis, Lars D. Engstrom, Jill Hallin
Supplementary Composite Figure File
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::095624453d8ad8530fb345958c4cd8b6
https://doi.org/10.1158/2159-8290.22535530.v1
https://doi.org/10.1158/2159-8290.22535530.v1
Autor:
Peter Olson, James G. Christensen, Kwok-Kin Wong, Adam Pavlicek, Julio Fernandez-Banet, Sole Gatto, Jill Hallin, Lars D. Engstrom, Jiehui Deng, David H. Peng, Lauren Hargis, Ruth Aranda, Niranjan Sudhakar, Andrew Calinisan, Shuai Li, David M. Briere
KRASG12C inhibitors, including MRTX849, are promising treatment options for KRAS-mutant non–small cell lung cancer (NSCLC). PD-1 inhibitors are approved in NSCLC; however, strategies to enhance checkpoint inhibitor therapy (CIT) are needed. KRASG12
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0679ee9794421d5e87ada96097d171a6
https://doi.org/10.1158/1535-7163.c.6543400.v1
https://doi.org/10.1158/1535-7163.c.6543400.v1
Autor:
Peter Olson, James G. Christensen, Kwok-Kin Wong, Adam Pavlicek, Julio Fernandez-Banet, Sole Gatto, Jill Hallin, Lars D. Engstrom, Jiehui Deng, David H. Peng, Lauren Hargis, Ruth Aranda, Niranjan Sudhakar, Andrew Calinisan, Shuai Li, David M. Briere
Figures S1-S7
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6ceca5b28312dd8892d9b8d8ba17873c
https://doi.org/10.1158/1535-7163.22522492
https://doi.org/10.1158/1535-7163.22522492
Autor:
James G. Christensen, Peter Olson, Pasi A. Jänne, Kyriakos P. Papadopoulos, Piro Lito, Sai-Hong Ignatius Ou, Melissa L. Johnson, Igor I. Rybkin, Matthew A. Marx, Douglas P. Cassidy, Emanuel F. Patricoin, Elisa Baldelli, Mariaelena Pierobon, Jeremy Barton, Richard C. Chao, Karen Velastagui, Adam Pavlicek, Julio Fernandez-Banet, Sole Gatto, Yaohua Xue, Guy P. Vigers, John P. Fischer, Jay B. Fell, Michael R. Burkard, Joshua A. Ballard, Brian R. Baer, Vickie Bowcut, Niranjan Sudhakar, David M. Briere, Ruth Aranda, Andrew Calinisan, Lauren Hargis, Lars D. Engstrom, Jill Hallin
Despite decades of research, efforts to directly target KRAS have been challenging. MRTX849 was identified as a potent, selective, and covalent KRASG12C inhibitor that exhibits favorable drug-like properties, selectively modifies mutant cysteine 12 i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dd866fa6fe03bc0849986ce88d5870c4
https://doi.org/10.1158/2159-8290.c.6547879.v1
https://doi.org/10.1158/2159-8290.c.6547879.v1
Autor:
Peter Olson, James G. Christensen, Kwok-Kin Wong, Adam Pavlicek, Julio Fernandez-Banet, Sole Gatto, Jill Hallin, Lars D. Engstrom, Jiehui Deng, David H. Peng, Lauren Hargis, Ruth Aranda, Niranjan Sudhakar, Andrew Calinisan, Shuai Li, David M. Briere
Supplementary Material
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::89313461352dbe1920a2daf9ea2d10c3
https://doi.org/10.1158/1535-7163.22522489
https://doi.org/10.1158/1535-7163.22522489
Autor:
Shilpi Khare, Niranjan Sudhakar, Jade Laguer, David M. Briere, Larry Yan, Allan Hebbert, Andrew Calinisan, Lars D. Engstrom, Fadia Qiryaqos, Peter Olson, James G. Christensen, Jacob R. Haling
Publikováno v:
Cancer Research. 83:3499-3499
Osimertinib is a third generation, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor recommended as a first line therapy in patients with advanced non-small lung cancer (NSCLC) characterized by EGFR activating mutations (
Autor:
Shilpi Khare, Niranjan Sudhakar, David M. Briere, Larry Yan, Lars D. Engstrom, Jade Laguer, James Medwid, Laura Vegar, Darin Vanderpool, Matthew A. Marx, John M. Ketcham, James G. Christensen, Peter Olson, Jacob R. Haling
Publikováno v:
Cancer Research. 82:LB193-LB193
KRAS is the most frequently mutated oncogene in human cancer and facilitates uncontrolled growth through hyperactivation of the MAPK pathway. Recent data has consistently demonstrated co-dependencies of mutant-KRAS with extrinsic proteins that augmen
Autor:
John M. Ketcham, David M. Briere, Aaron C. Burns, James G. Christensen, Robin J. Gunn, Jacob Haling, Anthony Ivetac, Shilpi Khare, Jon Kuehler, Svitlana Kulyk, Jade Laguer, John D. Lawson, Krystal Moya, Natalie Nguyen, Peter Olson, Lisa Rahbaek, Christopher R. Smith, Niranjan Sudhakar, Nicole C. Thomas, Darin Vanderpool, Xiaolun Wang, Matthew A. Marx
Publikováno v:
Cancer Research. 82:LB505-LB505
KRAS mutations are the most common activating mutations in human cancer that ultimately lead to hyperactivation of the MAPK pathway and uncontrolled growth. KRAS functions as a small GTPase that cycles through its GTP-loaded “on” state and its GD
Autor:
John M. Ketcham, Shilpi Khare, Niranjan Sudhakar, David M. Briere, Larry Yan, Jade Laguer, Laura Vegar, Darin Vanderpool, Jill Hallin, Lauren Hargis, Vickie Bowcut, David Lawson, Robin J. Gunn, Anthony Ivetac, Nicole C. Thomas, Barbara Saechao, Natalie Nguyen, Jeffrey Clarine, Lisa Rahbaek, Christopher R. Smith, Aaron C. Burns, Matthew A. Marx, James G. Christensen, Peter Olson, Jacob R. Haling
Publikováno v:
Cancer Research. 82:ND02-ND02
KRAS is the most frequently mutated oncogene in cancer and drives uncontrolled growth through hyperactivation of the MAPK pathway. Significant progress has been made in the past several years to directly target KRASG12C with the FDA approval of sotor